However, since PGC-1α regulates mitochondrial function, oxidative stress, and inflammation, all of which are essential processes involved in BPD-PH pathogenesis, it is highly likely that it could be an effective therapeutic target that could modify the development of BPD-PH (2, 71, 76). The gene discussed is PPARGC1A; the disease is bronchopulmonary dysplasia.